Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 1 Date: 13 Nov 2023
Reviewer's report:
The efficacy of Pembrolizumab + cisplatin + 5-FU for unresectable advanced esophageal cancer
has already been demonstrated in the KEYNOTE-590 trial. This paper is not well up to the
standard of BMC Gastroenterology, this paper should not be acceptable for the publication.
The definition of T4b is not explained in detail. Is it based on the TNM classification or Japanese
classification of Esophageal Cancer ?
Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 1 Date: 13 Nov 2023
Reviewer's report:
The efficacy of Pembrolizumab + cisplatin + 5-FU for unresectable advanced esophageal cancer
has already been demonstrated in the KEYNOTE-590 trial. This paper is not well up to the
standard of BMC Gastroenterology, this paper should not be acceptable for the publication.
The definition of T4b is not explained in detail. Is it based on the TNM classification or Japanese
classification of Esophageal Cancer ?
Please review this paper.
user
Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 1 Date: 13 Nov 2023
Reviewer's report:
The efficacy of Pembrolizumab + cisplatin + 5-FU for unresectable advanced esophageal cancer
has already been demonstrated in the KEYNOTE-590 trial. This paper is not well up to the
standard of BMC Gastroenterology, this paper should not be acceptable for the publication.
The definition of T4b is not explained in detail. Is it based on the TNM classification or Japanese
classification of Esophageal Cancer ?
assistant